Cerebrolysin

What it is

Cerebrolysin is not a single peptide. It is a mixture made by breaking down proteins from pig brain tissue into small peptides and free amino acids. It is a licensed medicine in some countries (including Austria, where it is made, and several in Eastern Europe, Asia and Latin America) but it is not licensed in the UK or the US.

In hospitals where it is used, it is given by infusion or injection in large volumes for stroke, traumatic brain injury and dementia. Studies suggest possible benefit in some areas, but results are inconsistent and many trials were small or of lower quality.

In nootropic circles it is used for memory and focus. There is little reliable evidence that it improves cognition in healthy people.

History

Cerebrolysin was developed in Austria in the 1950s and has been marketed since the 1970s. It has been used mostly in hospital settings in parts of Europe and Asia, and studied in stroke and dementia trials for several decades.

How it works

The idea is that small peptides in the mixture mimic nerve growth factors and support neurons, helping them survive and make connections. Animal and cell studies point to effects on nerve growth and protection. The exact active components are not defined, because it is a mixture, which is one reason it is hard to study and standardise.

Dosage

• Licensed regimens are given in millilitres of the liquid, not milligrams: commonly 10-50 ml per day by IV infusion for 10-20 days, in hospital. That is far more than any 60 mg research vial can supply.
• A 60 mg vial is not equivalent to a licensed ampoule. It is unclear what the 60 mg refers to (total solids or peptide content), and how it relates to licensed doses. We have low confidence in any dosing comparison.
• Community use for nootropic purposes reports courses of 10-20 days of daily injection, often followed by months off. These come from anecdote, not controlled trials.
• If you are considering it for stroke or dementia, this is a conversation for a specialist.

How it is taken

• Hospital use is by slow intravenous infusion. Injectable use by individuals is intramuscular or subcutaneous, and larger volumes can be painful.
• Injections should be given slowly. Rotate sites.

How to reconstitute

• For a lyophilised 60 mg vial, adding 2 ml of bacteriostatic water gives 30 mg/ml, which is 0.3 mg per unit on a 1 ml syringe. A 10 mg dose is about 33 units.
• Check the vial label for what the 60 mg refers to and the seller's own instructions, as this differs from the licensed liquid product, which is already in solution.
• Add the water gently and swirl. Do not shake.

How it should arrive

Licensed Cerebrolysin comes as sealed glass ampoules of clear liquid in a branded box with a batch number. A lyophilised research vial should be a sealed glass vial with a pale powder or cake.

How it should look once reconstituted

Clear liquid, pale yellow to brownish yellow (the licensed product is typically a light brownish colour). Cloudiness, particles or an unusual smell mean do not use it.

What to expect, and when

• In clinical trials, effects are assessed over weeks to months after a 10-20 day course.
• Nootropic users report effects within a week or two, but placebo is a significant factor in unblinded use.
• If you notice nothing after a full course, it probably is not doing anything for you.

Side effects

• Dizziness, headache, nausea, sweating.
• Agitation or anxiety, insomnia, especially at higher doses.
• Injection-site pain, and flushing if infused too fast.
• Allergic reactions, which can be serious. Because it is animal-derived, protein reactions are possible.

Risks

• It is made from pig brain tissue, which raises allergy risks, as well as religious and dietary concerns. Licensed manufacturing includes steps to reduce the risk of disease transmission, but unlicensed supplies do not offer the same assurance.
• Avoid in epilepsy or seizure history (it can lower the seizure threshold) and in severe kidney impairment.
• Not approved in the UK or US. Evidence is mixed: systematic reviews in stroke have not found clear, reliable benefit on survival or disability, while some dementia trials show small cognitive benefits. A lot of the supportive research was funded or run by the manufacturer or came from smaller trials.
• There is no good evidence of benefit in healthy people, so using it as a smart drug is speculation.
• Quality of unlicensed vials is hard to verify.

Potential gains

• Possible small benefits in cognition in mild to moderate Alzheimer's or vascular dementia in some trials, though results vary.
• Possible support in recovery after stroke or brain injury in some studies, but the highest-quality reviews are not convincing.
• Nootropic claims for memory and focus in healthy people are not backed by good trials.

Other useful information

Where it is licensed it is used by specialists in a hospital setting. If you or a family member are dealing with stroke or dementia, the best route is a neurology team, who can say what is available and what has real evidence behind it.